Skip to main content
. Author manuscript; available in PMC: 2023 Mar 1.
Published in final edited form as: J Control Release. 2022 Jan 22;343:267–276. doi: 10.1016/j.jconrel.2022.01.024

Figure 1: Schematic of combination of 131I-ELP brachytherapy and ELP-K12/CpG immunotherapy.

Figure 1:

ELP brachytherapy is formulated as a 131I radionuclide conjugated to Tyr residues at the C-terminus of an ELP (131I-ELP), while CpG is electrostatically complexed to a (Lys)12 peptide at the C-terminus of an ELP (ELP-K12). Each conjugate is injected i.t. and undergoes an LCST phase transition at body temperature to form ELP depots. The 131I is retained within the tumor because of radiation-induced crosslinking of the ELP and irradiates the tumor from the inside-out, while the electrostatically complexed CpG is released from the depot over time to activate immune signaling within the tumor.